Group 1 - The Tangshan High-tech Zone New Industry Development Fund has been established with a total investment of 5.01 billion RMB [1] - The fund's operational scope includes private equity investment, investment management, and asset management activities [1] - The fund is co-funded by the Tangshan High-tech Zone State-owned Holding Group Co., Ltd. and other contributors [1]

Group 1 - The Tangshan High-tech Zone New Industry Development Fund (Limited Partnership) has been established with a total investment of 501 million RMB [1][2] - The fund is managed by Beijing Qijian Private Fund Management Co., Ltd., and its business scope includes private equity investment, investment management, and asset management [1][2] - The fund's partners include Tangshan High-tech Zone State-owned Holding Group Co., Ltd., Beijing Qijian Private Fund Management Co., Ltd., and Hebei Robot Industry Fund (Limited Partnership) [1][2] Group 2 - The fund is classified as a limited partnership and is registered under the capital market services industry [2] - The fund's operational period is from August 6, 2025, to August 5, 2033 [2] - The fund must complete registration with the Asset Management Association of China before commencing its business activities [2]

天眼查App显示，近日，唐山高新区战新产业发展基金（有限合伙）成立，执行事务合伙人为北京骐健私募基金管理有限公司，出资额5.01亿人民币，经营 范围为以私募基金从事股权投资、投资管理、资产管理等活动。合伙人信息显示，该基金由唐山高新区国有控股集团有限责任公司、北京骐健私募基金管理 有限公司、河北省机器人产业基金（有限合伙）共同出资。 | ●大眼管 | | 都在用的 商业 查 询 工 具 | 章公司 童老板 童关系 查风险 | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | | | 国家中小企业发展子基金旗下机构 | 唐山高新区战新产业发展基金（有限合伙） | × | 天眼一下 | 船 应用 ▼ | 商务合作 | | 基本信息 3 | | 法律诉讼 | 经营风险 | 经营信息 | | 公司发展 | 知i | | 合伙人信息 3 ⑦ ● 品 股权结构 | | | | | | | | | 序号 | | | 合伙人名称 | | | 出资比例÷ | 认缴出资额 | | | | 北京骐健私募基金管理有限公司 器 | | | | | | | 1 | 具 ...

天眼查App显示，8月6日，唐山高新区战新产业发展基金（有限合伙）成立，执行事务合伙人为北京骐 健私募基金管理有限公司，出资额5.01亿人民币，经营范围为以私募基金从事股权投资、投资管理、资 产管理等活动。合伙人信息显示，该基金由唐山高新区国有控股集团有限责任公司、北京骐健私募基金 管理有限公司、河北省机器人产业基金（有限合伙）共同出资。 ...

Core Viewpoint - The medical device sector is experiencing a rise, with notable increases in stocks such as United Imaging Healthcare, New Industry, BGI Genomics, and Jiuan Medical, all rising over 3% [1] Group 1: Stock Performance - The ETF tracking the CSI All Share Medical Device Index has increased by approximately 3% [1] - Specific ETFs in the medical device sector have shown significant gains, with the Medical Device ETF Fund at 0.830, up 3.23%, and the Medical Device Index ETF at 0.588, up 3.16% [2] Group 2: Future Opportunities - Analysts indicate that increasing internationalization will provide more investment opportunities in the medical device sector, with several companies expected to see high growth in international business by 2025 [2] - The performance of Hong Kong's medical device stocks has been strong this year, which may positively influence the A-share market, suggesting that investment opportunities in both A-shares and Hong Kong's medical device sector will continue to emerge [2]

Group 1 - The A-share pharmaceutical sector is experiencing a rebound, with the Medical Innovation ETF (516820.SH) rising by 0.78% [1] - Key stocks such as Antu Bio (603658) increased by 6.18%, Mindray Medical (300760) by 2.61%, and Aimeike (300896) by 1.88% [1] - The Shanghai Regulatory Bureau and seven other ministries issued measures to promote the high-quality development of commercial insurance to support pharmaceutical innovation, encouraging the establishment of "patient capital" for long-term support of innovative drug research and development [1] Group 2 - The new measures have attracted over 100 drug applications for inclusion in the commercial health insurance innovative drug catalog, shifting the industry from a "single-driver" model to a "dual-driver" model of "medical insurance + commercial insurance" [1] - The national unified medical insurance big data platform, covering 1.3 billion insured individuals and over 300,000 types of drugs and consumables, is seen as a significant support for the development of the industry [1] - The platform aids in quickly analyzing clinical needs, enhancing drug value assessment, and accelerating the inclusion of innovative drugs into medical insurance, thus promoting the development of commercial insurance [1] Group 3 - Market dynamics are shifting, with funds moving from high-valued sectors to reasonably valued ones, leading to a gradual rebound of core assets at the bottom [2] - The medical innovation sector, including CXO (WuXi AppTec/TigerMed), medical devices (Mindray), and medical consumption (Aier Eye Hospital/Aimeike), is highlighted as having core assets that are significantly undervalued [2] - Weak U.S. economic and employment data may accelerate the Federal Reserve's rate cuts, enhancing global liquidity and benefiting technology stocks, presenting a good opportunity for investment in the medical innovation ETF (516820) [2]

（文章来源：证券日报） 证券日报网讯 8月6日晚间，新产业发布公告称，近日，公司收到了广东省药品监督管理局颁发的1项 《医疗器械注册证》，产品名称及型号：电解质分析仪（型号：BiossaysE6Plus）。 ...

Group 1 - The core viewpoint of the article is the issuance of measures to promote the high-quality development of commercial health insurance to support innovation in the biopharmaceutical industry [1] Group 2 - The measures aim to broaden the service population of commercial health insurance, focusing on the needs of the elderly, children, and patients with chronic diseases [1] - Insurance institutions are encouraged to include elderly individuals and those with pre-existing conditions in their coverage, based on controllable risks and commercial sustainability [1] - The use of big data and industry experience data is recommended to reasonably determine insurance product rates and to relax underwriting conditions [1] - There is an emphasis on providing diversified customized services and increasing health coverage for specific groups such as new citizens and those in emerging industries and business formats [1]

Core Viewpoint - The company has received a medical device registration certificate for its electrolyte analyzer, indicating a significant step in its product development and regulatory compliance [1] Company Summary - The company, 新产业 (300832), has been granted a medical device registration certificate by the Guangdong Provincial Drug Administration for its product, the electrolyte analyzer (model: Biossays E6 Plus) [1]

（文章来源：每日经济新闻） 2024年1至12月份，新产业的营业收入构成为：体外诊断占比99.82%，其他业务占比0.18%。 新产业（SZ 300832，收盘价：55.7元）8月6日晚间发布公告称，近日，深圳市新产业生物医学工程股 份有限公司收到了广东省药品监督管理局颁发的1项《医疗器械注册证》。产品名称为"电解质分析 仪"。 ...